

A new FACIT of the collagen family: COL21A1¹

Jamie Fitzgerald*, John F. Bateman

Cell and Matrix Biology Research Unit, Department of Paediatrics, University of Melbourne and the Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Vic. 3052, Australia

Received 24 July 2001; accepted 24 July 2001

First published online 29 August 2001

Edited by Veli-Pekka Lehto

Abstract Interrogation of the Human Genome data for sequences related to the von Willebrand factor A-domain module identified a previously unreported 4.1 kb full-length cDNA that is predicted to encode a new member of the collagen superfamily of extracellular matrix proteins, collagen XXI. The domain organization of collagen XXI comprised an N-terminal signal sequence, followed by single von Willebrand factor A-domain and thrombospondin domains, and an interrupted collagen triple helix. The organization of these motifs predict that collagen XXI is a new member of the FACIT collagen sub-family. Expression analysis indicated that COL21A1 mRNA is present in many tissues including heart, stomach, kidney, skeletal muscle and placenta, and radiation hybrid mapping localized the COL21A1 gene to 6p11-12. © 2001 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.

Key words: Fibril-associated collagen with interrupted triple helices; von Willebrand factor A-domain; Thrombospondin repeat; Interrupted collagen triple helix; Extracellular matrix

1. Introduction

The extracellular matrix (ECM) of connective tissues is a highly regulated tissue-specific network of collagens, non-collagenous proteins and glycoproteins, and proteoglycans. Many of these ECM components are composed of different combinations of characterized protein domains or modules [1]. The completion of the first draft of the Human Genome Project makes it feasible to identify new modular ECM proteins by database homology searching using these conserved modules as probes. It is anticipated that this strategy will help reveal the full complement of modular ECM proteins and proteoglycans that so far have eluded conventional biochemical identification.

One module present in a number of proteins is the type-A domain, first described in von Willebrand factor (reviewed in [2]). ECM components that contain one or more von Wille-

brand factor A-domains (VA) include fibril-associated collagen with interrupted triple helices (FACIT) collagens XII [3], XIV [4], and XX [5], collagens VI [6,7] and VII [8], matrilins 1–4 (reviewed in [9]), cochlin [10], polydom [11] and nine transmembrane α integrin chains. The VA domain is an independently folding protein module that attains a classic α/β 'Rossman' fold consisting of a parallel β sheet surrounded by amphipathic α helices and a metal-ion-dependent adhesion site (MIDAS) at the C-terminal end of the β sheet [12–14]. Although the role of VA domains has not been precisely defined, they appear to play an important role in protein–protein interactions [15–20].

To further define the molecular and biochemical roles VA domains play in ECM architecture and function, we searched the Human Genome database for novel VA-domain-containing proteins. In this report we describe COL21A1, a new VA-domain-containing collagen with a domain structure that predicts it is a member of the FACIT collagen sub-family expressed in various tissues including heart, stomach, placenta, skeletal muscle, kidney and liver.

2. Materials and methods

2.1. COL21A1 mRNA analysis

A poly(A)⁺ human multiple tissue expression (MTE) blot containing 76 tissues and cell lines (Clontech) was hybridized to a [³²P]dCTP random primer-labelled human COL21A1 polymerase chain reaction (PCR) product amplified from the COL21A1 cDNA clone obtained from the German cDNA Consortium (GenBank accession number NM_030820). The 642 bp probe was generated using COL21A1F1 (3247 5'-GCTCCTCAGTCATTTGGAGC-3'3266) and COL21A1R1 (3889 5'-TGGACATGCACATASTAAGTG-3'3870) primers designed to anneal within the 3' untranslated region of the COL21A1 cDNA. The numbering of nucleotides is from the start of the clone including the 5' untranslated region (see Fig. 1A). The PCR was performed in a 50 μ l reaction volume with 100 ng of COL21A1 template cDNA, 1.5 mM MgCl₂ and 2.5 units of *Taq* polymerase (Perkin Elmer) at 94°C for 5 min, followed by 36 cycles of 94°C for 30 s, 58°C for 30 s, 72°C for 30 s, and a final extension at 72°C for 7 min. Following overnight hybridization at 65°C in ExpressHyb hybridization solution (Clontech), the blot was washed four times in 1×SSC/1% SDS (w/v) at 65°C, then twice in 1×SSC/0.5% SDS (w/v) at 55°C, exposed to a phosphor-screen for 2–4 days and scanned with a Storm phosphor-imager (Molecular Dynamics). The blot was stripped and re-probed with a ubiquitin cDNA to confirm that approximately equal amounts of poly(A)⁺ RNA were loaded on each dot.

A Northern blot containing poly(A)⁺ RNA (2 μ g per lane) from 12 human tissues (Clontech) was probed with the [³²P]dCTP random primer-labelled human COL21A1 PCR product in ExpressHyb hybridization solution. The blot was washed to a stringency of 0.1×SSC/0.1% SDS (w/v) at 55°C and exposed to a phosphor-screen as described above. The blot was stripped and re-probed with a human β -actin control cDNA to demonstrate that each lane contained approximately equal amounts of poly(A)⁺ RNA.

*Corresponding author. Fax: (61)-3-9345 7997.

E-mail address: fitzgerj@cryptic.rch.unimelb.edu.au (J. Fitzgerald).

¹ The collagen 21 DNA (and protein) sequence has been deposited in GenBank (accession number AF414088).

Abbreviations: FACIT, fibril-associated collagen with interrupted triple helices; ECM, extracellular matrix; VA, von Willebrand factor A-domain; TN, thrombospondin domain; COL, collagenous domain; NC, non-collagenous domain; MTE, multiple tissue expression; PCR, polymerase chain reaction

2.2. Chromosomal mapping of the human COL21A1 gene

The chromosomal location of the COL21A1 gene was determined by radiation hybrid mapping [21] using the Genebridge 4 radiation hybrid panel. Primers and amplification conditions were the same as those used to generate the PCR probe for MTE and Northern analysis. The results were submitted to the Sanger Centre (<http://www.sanger.ac.uk/software/rhserver>) for scoring using 2-pt RMAP software [22].

3. Results and discussion

3.1. Identification of COL21A1 cDNA

To identify novel VA-domain ECM proteins, the non-redundant database at the National Center of Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/blast/>) was interrogated with the N-terminal VA-domain protein sequence of human matrilin-1 using the blastp program (v2.0). One of the highest scoring hits, with an *E* value of 4×10^{-24} , was a cDNA sequence encoding a previously unreported collagen-like gene (GenBank accession numbers for the protein and nucleotide sequences are NP_110447 and NM_030820, respectively). This cDNA clone, which had been isolated and sequenced in full by the German cDNA consortium (<http://www.rzpd.de/>), was predicted to contain an uninterrupted protein coding region based on identification of a complete open reading frame and a poly(A) tail at the 3' end of the clone. To test the accuracy of the reported NM_030820 nucleotide sequence, it was used to interrogate the Human Genome database at NCBI. Multiple hits were scored within a BAC (NT_007336) clone assigned to a working draft of chromosome 6 by the Sanger Centre. Inspection of the aligned NM_030820 cDNA and two Sanger Centre genomic clones (RP4-708F5 and RP1-181C24) revealed a nucleotide discrepancy (A to C change at nucleotide 587) between the cDNA and the two genomic clones, which is predicted to alter the amino acid sequence (Asp to Ala). Interrogation of the Human EST database revealed that in an EST sequence (BG699698) that covered this region, a C nucleotide was present at nucleotide 587, thus confirming the BAC sequences and suggesting that the nucleotide difference in the cDNA clone is either a cloning artefact or a polymorphism. Furthermore, since the alignment of the cDNA and genomic DNA provides information about the position and size of exons and introns, we can predict that this gene is approximately 190 kb in size and is composed of 30 exons.

Initial inspection of the predicted protein sequence revealed that it contains two significant repeating Gly-X-Y motifs of 339 and 112 amino acids in the C-terminus (Figs. 1A and 2A), identifying it as a new member of the collagen family of ECM proteins. We followed the traditional naming system for collagens and assigned it the next sequential number, XXI.

3.2. Features of COL21A1 DNA and predicted protein sequence

The COL21A1 cDNA is 4141 bp in size, exclusive of the poly(A) tail, with a predicted start methionine at nucleotides 203–205 and a TAG stop codon at nucleotides 3074/3076 (Fig. 1A). The deduced open reading frame is 2873 bp in size with 202 bp of 5'UTR and 1066 bp of 3'UTR.

The COL21A1 open reading frame encodes a 957 amino acid protein with a predicted molecular weight of 99 kDa. A 22 amino acid signal sequence with a cleavage site between Ala²² and Glu²³ is predicted by SignalP signal sequence pre-

A GGGGGCCCGCTGCGAGGAGAACGGACTCGGGCGGAGGCGAGCAATCCGTTTCAGCGCA 60
GGTCTTGGCTGGGTTGGGCTTGGCACTGCTGGAGCAATACCTGTCCTCCCTGGCGCAACAC 120
TCAGCTGGCTGGCGAGCGCAACCCGAGGCTGGACATCGGCGAGGAATCTTAAACCAAA 180
ATATTAGCAAGAAACAGAAACATGGCTGGCTTATATACATTTCTGTCATGGTTTGGT 240
M A H Y I T F L C M V L V 13
GCTGCTTCTCAGAATTCTGTGTAGCTGAAGATGGGGAAGTAAGATCAAGTTGTCGTAC 300
L L L Q N S V L A E D G E V R S S C R T 33
TGCTCCGACAGATTAGTTTTCATCTTATAGTGGCTCTTATAGTGTGGCCGAGAAACIT 360
A P T D L V F I L D G S Y S V G P E N F 53
TGAATATGAAAAAGTGGCTGTGCAATATCAGAAAAAATCTTGACATAGGCGCAAGTT 420
E I V K K W L V N I T K N F D I G P K F 73
TATTCAAGTTGGAGTGGTTCAATATAGTAGTACCTGCTGGAGATTCCTCTCGGAG 480
I Q V G V V Q Y S D Y P V L E I P L G S 93
CTATGATTAGGGAACATTTCAGCGCAGCAGTGGAAATCCATCTACTTACCTAGGAGAA 540
Y D S G E H L T A A V E S I L Y L G G N 113
CACAAGACAGGGAAGGCCATCCAGTTTGGCTCGATTAACCTTTTGGCAAGTCTCCAGC 600
T K T G K A I Q F A L D Y L F A K S S R 133
ATTTCGACTAAGTAGCAGTGGTACTTACCGATGGCAAGTCCCAAGATGACCTCAAGGA 660
F L T K I A V V L T D G K S Q D D V K D 153
TGACGCTCAAGCAGCAGAGATAGTAGTAATACATTAATTTGCTATTTGGTGTGGTTGAGA 720
A A Q A A R D S K I T L F A I G V G S E 173
AACAGAGATGCGCAACTTACAGCTTATGGCAACAGGCTCTGCTTACTTATGTGTGTTA 780
T E D A E L R A I A N K P S S T Y V F Y 193
TGTGGAAGACTATATGCAATATCAGAAATAGGGAAGTGATGAGCAGAACTTTGTGA 840
V E D Y I A I S K I R E V G M K Q K L C E 213
AGAATCTGTCTGCAACAGAAATCCAGTGGCAGCTCTGATGAGAAAGGGGATTTGATAT 900
E S V C P T R I P V A A R D E R G F D I 233
TCTTTTGGGTTTAGATGTAAATAAAAGGTAGAAAGAAATACAGCTTTTACCAAAAAA 960
L L G L D V N K K V K R I Q L S P K K 253
GATAAAGGATATGAAGTAACATCAAAATGTATTTATCAGAACTCAGCAGCAATGTTTT 1020
I K G Y E V T S K V D L S E L T S N V F 273
CCAGAAAGCTCTCTCCATCATATGTTCTGTCTCTCAAGAGATTAAAGTCAGAA 1080
G E L P P S Y V F V S T Q R F K V K K 293
AATTGGGATTATGAGAAATTAATCTTATGAGGAGGCAACAAATAGCATTACCTT 1140
I W D L W R I L T I D G R P Q I A V T L 313
AAATGCTGTGGGCAAAATCTTATTAATTAACAACACAGGCTGAATTAATGGCTCAAGT 1200
N G V D K I L L F T T T S V I N G S Q V 333
GGTTACTTTTGTCAACCTCAAGTTAAGACGTGTGTATGATGAGGCTGGCAGCAATTCG 1260
V T F A N P Q V K T L F D E G W H Q I R 353
TCTCTTATGAACAGCAAGATGTGATCTTGTATGTATGATGACCAACAAATTTGAAACAA 1320
L L V T E Q D V T L Y I D G Q Q I E N K 373
GCCCTTACATCAGTTTATGAGGATCTTGTATCAATGGGCAACCAAAATGGAATAATTC 1380
P L H P V L G I L I N A G Q T Q I G K Y S 393
TGAAGAAGAAAGAACTGTTCAGTTTGTATGTCAGAAAGTTCGAAATCTACTGTGACCCAGA 1440
G K E E T V Q F D V Q K L R I Y C D P E 413
ACAGAAACACCGGAGACAGCATGTGAGATTCCTGGAATTTAATGAGAGAGCTTAAATG 1500
Q N N R E T A C G F N G E C I N G 433
TCCGATGATGTGCTCACTCAAGCTCTGTATTTCTCTCCGAGAAACAGGAGT 1560
P S D V G S T P A P G I C P G K P G L 453
TCAAGGCCCAAGGTGACCTGAGTCTGCTGGAACTCTGCTACCTTGGACCACTCG 1620
Q G P K G D P G L P G N G Y P G Q P G 473
TCAAGATGTGAAGCTGATATCAGGGAATTCAGGAGCAGCAGGTGTTCCAGGATCTCC 1680
Q D G K P G Y Q G I A G T P G V P G P 493
AGGAATCAAGGAGCTCAGGAGTCAAGGTACAAAGGAGAACAGGCGAGATGTGTA 1740
G I Q G A R G L P G Y K E E P G R D G D 513
CAAGGTGATCTGAGTCTCTGTTTCTGGGCTCTAGGATGCGAGATCAAGAGG 1800
K G D R G L P G P G L H G M P G S K G 533
TGAAATGGTCCCAAGGAGACAAAGGATCACTGGAATTTATGCGCAAAAGGAGTCGAA 1860
E M G A K G D K G N Q G P G Y G K K G A K 553
AGGTGAAAGGGAAGTCTGGCTCTCCCTGGCTCTGAGATCTGAGGAGCAGGAG 1920
G E K N A G P P G L P G A G E P R 573
ACATGGAAGAGGATTAATGGGTAGTCCCGGTTTCAAGGAGGAGCAGGATCCCTGG 1980
H G K D G L M G S P G F K G E A G S P 593
TGCTCCGGGCGAGATGAGACAGGAGAGCTGAGTCCAGGATCTCCGAGATCTCGAG 2040
A P G D G E G G I P F P N R 613
AGGATTAATGGGCAAAAGGAGAAATTTGGGCTCTCAGGACAGCAAGAAAGAGGAGC 2100
G L M G Q K G E I G P P G Q Q G K K G A 633
CCCAGGAGTCTGCTTTAATGGGAAGCAATGGCTCACAGGCGAGCTGGAAACACCGG 2160
P G M P G L M G S N G S P G Q P G T P G 653
ATCTAAGGAGCAAGGATGAACCTGGAATTCAGGAGTCTGCTGGGCTCTCAGGCTCAA 2220
S K G S K G E P G I Q G M P G A S G L K 673
GGGAGAACAGGAGCAACGGGTTCCAGGAGACAGGATACATGGTTTACCGGGAT 2280
G E P G A T G S P G E P G Y M G L P G I 693
TCAAGGAAAGAGGGGCAAGGAAATCAAGGTGAAAGGATTTACAGGTCAAAAGG 2340
Q G K K G D K G N Q G K E K I Q G Q K G 713
AGAAATGGAAGACAGGGAATTCAGGCGCAACAGGGAATCAAGGCCATCATGTGCAAA 2400
E N G R Q G I P G Q Q G I Q G H H G A K 733
AGGAGAGAGGAGTGAAGAGGAGAGCTGTGTCCAGGTGCAATTTGATCAAAAGAGGA 2460
G E R G E K G E G P G V R G A T G S G P 753
ATCTCGGGTGGATGCTTGTAGTGGGCGGAGCTTAAGAGGCAACCTCGGATCTCAGG 2520
G A V D G C P K G P G P G D P G 773
TCTCTCAGGACCCAGGTTTGTATGGAAGCGGAGAGAGTTCAGAACAAATTTAT 2580
P Q G P P G L D G K P G R E F S E Q I F 793
TGACAGATTTGACAGATTAATAGAGCCAGTACAGTCTTACTTACAGATGGAAG 2640
R Q V C T D V I R A Q L P V L L Q S G R 813
AATTAGAATTTGTGATCTGCTGCTCCCAACATGGCTCCCGGTTATCTCTGGGCAAC 2700
I R N C D H C L S Q H G S G P I P G P 833
TGGTCCGATAGGCCAGAGGTCAGAGGATTAACCTGTTTTCAGGAGAGAGATGGTGT 2760
G P I G P E G P R G P G L P G R D G V 853
TCTGTGATTTAGTGGGTGCTCTGAGCTGACAGGTTCAGAGGATTAAGAGCCCTACAGG 2820
P G L V G V P G R P G V R G L K G L P G 873
AAGAAATGGGAAAGGAGGAGCGGTTTGGGTATCTTGGAGAACAGGTCTCTCTGG 2880
R N G E K G S Q G F T G Y G E G P P G 893
TCCCGCAGTCCAGAGGCGCTCTGGAATTAAGCAAGAGGCTCTCCAGGAGAACCCAGG 2940
P P G E G P P G I S K E G P P G D P G 913
TCTCCCTGCAAGATGGAGACATGGAACCTGGAATTCAGAGGCAACAGGCGCCCC 3000
L P G K D G D H G K P G I Q G Q P G P 933
AGGCATCTGCGACCATCACTATGTTTATGTTAATTTGCGAGAGAGATCCGTTCAAGAA 3060
G I C D P S L C F S V I A R R D P F R K 953
AGAGCAAACTATTAGTGTCTGATGCTCATTCAGCAGCTAGGATGGTCTTTTCTG 3120
G N Y * 957
TGCTGTTTTTCATCTCAGGAAGATAACCAAGATCTCTCTTGAAGAAACCTTAAGTAC 3180
TCGTTGTTTTTATTTTTTTTCTTATGGAATAAATAAAGATACATATCTACTGAT 3240
TTAAAGGCTCTCAGTCATTTGAGGCTCTTGTATAGCAGCATTAATTAATCTCAAGG 3300
TTTCTGTGAAGTCTATTTATGTTAATCAAGTTGAATATAAAATCCACCATTTGCTGT 3360
TAGCCAGTCAAGTTTATGCTACTGTGAATATTTACATTTAGCTAGTCAATGCTAGTAC 3420
TTGAGTTTAAATTTATGCTCATGTGACTTTTCATGTTTCTATCTCATAGCTCATGCTACT 3480
ACATAAGCCAAACATGATATCTCATCATTTGGAAGTAAGATCAGGCTGATATTTCACTGG 3540
GATAGACAGTATTTGTAATCTACTCATTTACTACAGTGTCTCAGCTTGTATAAGGAGCAG 3600
TGGATTGCTGTGTTGCGTGTGTGAATAGACACTCTGATAAGATAGATGTTTCTTCT 3660
AATTCATTTCAAACTCTAAATTAGATTAATGGTGTGCTAAGAAAGAGATTAATTAATCT 3720
TTGGGAATGTAAGAAATTAACATTAAGAAATTTACATTTAGCTGACTGTAAGAAATTTATGAACAGCTC 3780
AAGAGAAATGTAGTTTGAAGATCAATAAGACTATTTTATATCTTTGTGATTAATCGGAA 3840
TGTTTGTGTATGCTCTTCAATTTTCACTTATATGTCATGTGTCATATGTTTAAAT 3900
TTTCTATGTAGCAAGCTTAATGGAATTAAGCTTAATGCTGTAGTTGAAGAAAGAGAAAT 3960
CTCTGGAATCTAGAAATGCTTGTATTTTATGCTGACTGTAAGAAATTTATGAACAGCTC 4020
TTTGTGATTTGCTGTTTATGCTTTTGTAGAAACAGATTTGAATAATTTTCTATCTCTG 4080
ATGCTCAAAATTTTGTATGCTCTTATTTTATGAGGATATAAAGTTTGTGTCAGGCTCT 4140
GAAAAAAGAAAAAAGAAAAA - 4160




Fig. 3. Expression pattern of COL21A1 mRNA in human adult and fetal tissues and cell lines. A: MTE analysis. Probes for COL21A1 (left) and a ubiquitin control (right) were hybridized to a human MTE array of poly(A)⁺ RNA from whole brain (A1), cerebral cortex (B1), frontal lobe (C1), parietal lobe (D1), occipital lobe (E1), temporal lobe (F1), paracentral gyrus (G1), pons (H1), left cerebellum (A2), right cerebellum (B2), corpus callosum (C2), amygdala (D2), caudate nucleus (E2), hippocampus (F2), medulla oblongata (G2), putamen (H2), substantia nigra (A3), nucleus accumbens (B3), thalamus (C3), pituitary gland (D3), spinal cord (E3), heart (A4), aorta (B4), left atrium (C4), right atrium (D4), left ventricle (E4), right ventricle (F4), inter-ventricular septum (G4), apex (H4), esophagus (A5), stomach (B5), duodenum (C5), jejunum (D5), ileum (E5), ileocecum (F5), appendix (G5), ascending colon (H5), transverse colon (A6), descending colon (B6), rectum (C6), kidney (A7), skeletal muscle (B7), spleen (C7), thymus (D7), peripheral blood leukocytes (E7), lymph node (F7), bone marrow (G7), trachea (H7), lung (A8), placenta (B8), bladder (C8), uterus (D8), prostate (E8), testis (F8), ovary (G8), liver (A9), pancreas (B9), adrenal gland (C9), thyroid gland (D9), salivary gland (E9), mammary gland (F9), leukemia HL-60 cells (A10), HeLa S3 cells (B10), leukemia K-562 (C10), leukemia MOLT-4 cells (D10), Burkitt's lymphoma (Raji) (E10), Burkitt's lymphoma (Daudi) (F10), SW480 colorectal adenocarcinoma (G10), A549 lung carcinoma (H10), fetal brain (A11), fetal heart (B11), fetal kidney (C11), fetal liver (D11), fetal spleen (E11), fetal thymus (F11), fetal lung (G11). B: Northern blot analysis. Probes for COL21A1 (top panel) and a β -actin control (bottom panel) were hybridized to a multiple tissue Northern blot containing approximately 2 μ g of poly(A)⁺ RNA from peripheral blood leukocytes (1), lung (2), placenta (3), small intestine (4), liver (5), kidney (6), spleen (7), thymus (8), colon (9), skeletal muscle (10), heart (11) and brain (12). RNA markers (kb) are indicated on the right. In most tissues, β -actin is present as a 2.0 kb transcript, except in skeletal muscle and heart where an additional 1.8 kb transcript is present.

and septum of the heart also expressed high mRNA levels. Re-probing the blot with a ubiquitin cDNA confirmed that approximately equal amounts of mRNA were present on each dot. This pattern of COL21A1 mRNA expression closely corresponds to that of the three chains of collagen V, COL5A1, COL5A2 and COL5A3 [29]. Since the MTE analysis does not provide information about transcript size, we also probed a Northern blot containing mRNA from some of the human tissues that were positive for COL21A1 on the MTE blot (Fig. 3B). COL21A1 mRNA was detected in heart, placenta, jejunum, skeletal muscle, colon, kidney, liver, lung and absent or present at low levels in brain, spleen, thymus and peripheral leukocytes, confirming the pattern of expression determined by MTE analysis. In most of these tissues, a 4.2 kb

transcript was present, which is in good agreement with the size of the 4142 bp NM_030820 cDNA clone, confirming that it represents the full-length sequence. Interestingly, in heart and skeletal muscle, an additional 2.4 kb band was present that probably represents a splicing variant of the COL21A1 gene. Densitometric estimation using the phospho-imager indicated that in skeletal muscle, the two splicing variants were present in approximately equal amounts, but in heart, the 2.4 kb variant was 30-fold more abundant than the 4.2 kb version. When the Northern blot was re-probed with β -actin cDNA, a 2.0 kb transcript was detected in all tissues, confirming that approximately equal amounts of RNA were present in each lane.

In summary, analysis of the predicted amino acid sequence and the domain structure indicates that collagen XXI belongs to the FACIT sub-family of collagens and is the smallest member of this group reported to date. The mRNA expression data demonstrated that collagen XXI is present in tissues containing abundant ECM and in particular, in tissues expressing a muscle phenotype such as heart, skeletal muscle, and smooth muscle including stomach and jejunum, and in placenta, which has a large blood vessel network. These tissue are also enriched for collagen I and at least two members of the FACIT collagen family, collagens XII and XIV, have been shown to co-localize with collagen I [30,31] although a direct interaction has yet to be demonstrated [32]. This data raise the exciting possibility that co-expression of collagen XXI with collagen I in muscle and other tissues may by analogy with some of the other FACIT collagens, playing a role in the organization of interstitial collagen fibrils.

3.5. Chromosomal assignment of human COL21A1 gene

COL21A1 gene location was determined by radiation hybrid mapping [21], using PCR analysis of the Genebridge 4 radiation hybrid panel. COL21A1 mapped to marker AF-M205yc7 with a maximum LOD score of 9.6, which places the gene on chromosome 6p11-12. While no characterized connective tissue disorder maps to 6p11-12, the importance of FACIT collagens in ECM structure and function has been demonstrated by the characterization of mutations in collagen IX (COL9A2 and COL9A3) in multiple epiphyseal dysplasia [33,34]. The marker, AFM205yc7, is a CA-repeat polymorphism with a maximum heterozygosity of 0.8298, and will be useful in screening families for linkage between COL21A1 and potential disease phenotypes.

Acknowledgements: This work was supported by grants from the National Health and Medical Research Council of Australia and the Murdoch Childrens Research Institute. We thank the German cDNA Consortium for generously providing cDNA clone NM_030820.

References

- [1] Engel, J., Efimov, V.P., and Maurer, P. (1994) Dev. Suppl., 35–42.
- [2] Colombatti, A., Bonaldo, P. and Doliana, R. (1993) Matrix 13, 297–306.
- [3] Yamagata, M., Yamada, K.M., Yamada, S.S., Shinomura, T., Tanaka, H., Nishida, Y., Obara, M. and Kimata, K. (1991) J. Cell Biol. 115, 209–221.
- [4] Trueb, J. and Trueb, B. (1992) Eur. J. Biochem. 207, 549–557.
- [5] Koch, M., Foley, J.E., Hahn, R., Zhou, P., Burgeson, R.E., Gerecke, D.R. and Gordon, M.K. (2001) J. Biol. Chem. 276, 23120–23126.

- [6] Hayman, A.R., Koppel, J., Winterhalter, K.H. and Trueb, B. (1990) *J. Biol. Chem.* 265, 9864–9868.
- [7] Chu, M.L., Zhang, R.Z., Pan, T.C., Stokes, D., Conway, D., Kuo, H.J., Glanville, R., Mayer, U., Mann, K., Deutzmann, R. and Timpl, R. (1990) *EMBO J.* 9, 385–393.
- [8] Parente, M.G., Chung, L.C., Ryyanen, M., Woodley, D.T., Wynn, K.C., Bauer, E.A., Mattei, M.-G., Chu, M.-L. and Uitto, J. (1991) *Proc. Natl. Acad. Sci. USA* 88, 6931–6935.
- [9] Deak, F., Wagener, R., Kiss, I. and Paulsson, M. (1999) *Matrix Biol.* 18, 55–64.
- [10] Robertson, N.G., Skvorak, A.B., Yin, Y., Weremowicz, S., Johnson, K.R., Kovatch, K.A., Battey, J.F., Bieber, F.R. and Morton, C.C. (1997) *Genomics* 46, 345–354.
- [11] Gilges, D., Vinit, M.A., Callebaut, I., Coulombel, L., Cacheux, V., Romeo, P. and Vigon, I. (2000) *Biochem. J.* 352, 49–59.
- [12] Emsley, J., Cruz, M., Handin, R. and Liddington, R. (1998) *J. Biol. Chem.* 273, 10396–10401.
- [13] Lee, J.-O., Rieu, P., Arnaout, M.A. and Liddington, R. (1995) *Cell* 80, 631–638.
- [14] Qu, A. and Leahy, D.J. (1995) *Proc. Natl. Acad. Sci. USA* 92, 10277–10281.
- [15] Pareti, F.I., Niiya, K., McPherson, J.M. and Ruggeri, Z.M. (1987) *J. Biol. Chem.* 262, 13835–13841.
- [16] Hoylaerts, M.F., Yamamoto, Y., Nuyts, K., Vreys, I., Deckmyn, H. and Vermeylen, J. (1997) *Biochem. J.* 324, 185–191.
- [17] Kamata, T., Liddington, R.C. and Takada, Y. (1999) *J. Biol. Chem.* 274, 32108–32111.
- [18] Specks, U., Mayer, U., Nischt, R., Spissinger, T., Mann, K., Timpl, R., Engel, J. and Chu, M.-L. (1992) *EMBO J.* 11, 4281–4290.
- [19] Fitzgerald, J., Morgelin, M., Selan, C., Wiberg, C., Keene, D.R., Lamande, S.R. and Bateman, J.F. (2001) *J. Biol. Chem.* 276, 187–193.
- [20] Chen, Q., Zhang, Y., Johnson, D.M. and Goetinck, P.F. (1999) *Mol. Biol. Cell* 10, 2149–2162.
- [21] Walter, M.A., Spillet, D.J., Thomas, P., Weissenbach, J. and Goodfellow, P.N. (1994) *Nat. Genet.* 7, 22–28.
- [22] Boehnke, M., Lange, K. and Cox, D.R. (1991) *Am. Hum. Genet.* 49, 1174–1188.
- [23] Nielson, H., Engelbrecht, J., Brunak, S. and von Heijne, G. (1997) *Protein Eng.* 10, 1–6.
- [24] Hansen, J.E., Lund, O., Engelbrecht, J., Bohr, H., Nielsen, J.O., Hansen, J.-E.S. and Brunak, S. (1995) *Biochem. J.* 308, 801–813.
- [25] Ricard-Blum, S., Dublet, B. and van der Rest, M. (2000) *Unconventional Collagens: Types VI, VII, VIII, IX, X, XII, XIV, XVI and XIX*, 1st edn., Oxford University Press, Oxford.
- [26] Shaw, L.M. and Olsen, B.R. (1991) *Trends Biochem. Sci.* 16, 191–194.
- [27] Moradi-Ameli, M., Deleage, G., Geourjon, C. and van der Rest, M. (1994) *Matrix Biol.* 14, 233–239.
- [28] Shaw, L.M. and Olsen, B.R. (1991) *Trends Biochem. Sci.* 16, 191–194.
- [29] Imamura, Y., Scott, I.C. and Greenspan, D.S. (2000) *J. Biol. Chem.* 275, 8749–8759.
- [30] Schuppan, D., Cantaluppi, M.C., Becker, J., Veit, A., Bunte, T., Troyer, D., Schuppan, F., Schmid, M., Ackermann, R. and Hahn, E.G. (1990) *J. Biol. Chem.* 265, 8823–8832.
- [31] Keene, D.R., Lunstrum, G.P., Morris, N.P., Stoddard, D.W. and Burgeson, R.E. (1991) *J. Cell Biol.* 113, 971–978.
- [32] Brown, J.C., Mann, K., Wiedemann, H. and Timpl, R. (1993) *J. Cell Biol.* 120, 557–567.
- [33] Muragaki, Y., Mariman, E.C., van Beersum, S.E., Perala, M., van Mourik, J.B., Warman, M.L., Olsen, B.R. and Hamel, B.C. (1996) *Nat. Genet.* 12, 103–105.
- [34] Paassilta, P., Lohiniva, J., Annunen, S., Bonaventure, J., Le Merrer, M., Pai, L. and Ala-Kokko, L. (1999) *Am. J. Hum. Genet.* 64, 1036–1044.
- [35] Bork, P. and Bairoch, A. (1995) *Trends Biochem. Sci.* 20, poster C02.
- [36] Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994) *Nucleic Acids Res.* 22, 4673–4680.